Translational and Basic Science Research in Early Lesions (TBEL) (U54 Clinical Trial Not Allowed) | RFA CA 21 054

Opportunity Information: Apply for RFA CA 21 054

The Translational and Basic Science Research in Early Lesions (TBEL) program is a National Institutes of Health funding opportunity designed to push cancer research earlier in the disease timeline, focusing on precancers and early cancers rather than fully developed malignancies. Its central idea is that tumor initiation and progression are not driven by the abnormal cells alone, but by an interacting system that includes the early lesion itself, the surrounding local microenvironment, and broader host or systemic factors (for example, immune function, inflammation, metabolism, hormones, microbiome influences, and other whole-body conditions). TBEL supports research that can tease apart direct causal relationships among these components to explain why some early lesions are restrained or eliminated while others progress toward invasive cancer.

A key aim of the program is to integrate basic science and translational science in a tightly connected, back-and-forth way. In practical terms, this means TBEL Centers are expected to generate mechanistic insights (basic biology of early lesions and their ecosystems) and then iteratively connect those findings to translational directions that could inform real-world prevention strategies. The end goal is to enable biology-backed precision prevention, meaning prevention approaches that are tailored to the specific biology and malignant potential of a given early lesion, instead of using one-size-fits-all screening or intervention models. The program emphasizes understanding both the drivers of progression and the mechanisms that restrain or suppress malignancy, since both sides of that balance can reveal opportunities for intervention.

This opportunity uses the U54 Specialized Center Cooperative Agreement mechanism, which generally indicates a center-style award with multiple integrated components and substantial scientific coordination, often including close collaboration and involvement from the funding agency compared to a standard research grant. Under TBEL, each funded TBEL Center must have a distinctive thematic focus and a structure built around testing hypotheses that deliberately bridge basic and translational research. The expectation is that projects within a Center will be synergistic rather than standalone, producing an integrated picture of early lesion biology and generating insights that can be used to guide future intervention concepts. Importantly, the opportunity is labeled Clinical Trial Not Allowed, signaling that the supported work should not include clinical trials as defined by NIH policy, even though it is intended to be translational and prevention-oriented.

TBEL Centers are also intended to function collectively as a coordinated network. In addition to what each Center discovers within its theme, the program is set up so that Centers together inform future intervention strategies that are rationally designed from strong biological mechanisms. The vision is for intervention concepts to be comprehensive and multi-dimensional, reflecting the reality that early cancer development is shaped by many interacting factors, and to be appropriately tailored to the degree of malignant potential in the lesion being studied. In other words, the network is meant to build the kind of foundational, mechanistic evidence needed to decide when and how to intervene, and for whom intervention is most warranted.

Administrative details from the source information include the funding opportunity title Translational and Basic Science Research in Early Lesions (TBEL) (U54 Clinical Trial Not Allowed) and the funding opportunity number RFA-CA-21-054. The instrument type is a Cooperative Agreement, and the activity category is listed under Education and Health, with CFDA numbers 93.394 and 93.396. The NIH is the sponsoring agency. The opportunity was created on 2021-08-31, and the original closing date was 2021-11-02. The listed award ceiling is $1,000,000, and the expected awards field is shown but not specified in the provided text.

Eligibility is broad and includes many types of domestic applicants such as state, county, and local governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; nonprofits with and without 501(c)(3) status (other than institutions of higher education); for-profit organizations (other than small businesses); and small businesses. It also includes Native American tribal governments (federally recognized) and other Native American tribal organizations (not federally recognized), as well as public housing authorities and Indian housing authorities. In addition, the opportunity explicitly calls out other eligible applicant categories, including Alaska Native and Native Hawaiian Serving Institutions, AANAPISIs, Hispanic-serving Institutions, Historically Black Colleges and Universities, Tribally Controlled Colleges and Universities, faith-based or community-based organizations, eligible federal agencies, U.S. territories or possessions, regional organizations, and even non-U.S. entities (foreign organizations). Overall, the structure and eligibility suggest the program is designed to bring together diverse institutions and capabilities to tackle early cancer biology with coordinated, mechanism-driven center research.

• The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Translational and Basic Science Research in Early Lesions (TBEL) (U54 Clinical Trial Not Allowed)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.394, 93.396.
• This funding opportunity was created on 2021-08-31.
• Applicants must submit their applications by 2021-11-02. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $1,000,000.00 in funding.
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for RFA CA 21 054

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: